Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs - Wikidata - wikimedia - TriplyDB

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

http://www.wikidata.org/entity/Q34093824

about

Long-term opioid management for chronic noncancer pain Rofecoxib for osteoarthritis COX-2 inhibitors: a CLASS act or Just VIGORously promoted New horizons and perspectives in the treatment of osteoarthritis Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach COX-2: where are we in 2003?--distinction from NSAIDs becoming blurred Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports Polypharmacy in Older Adults With Hypertension: A Comprehensive Review Anemia and iron deficiency in gastrointestinal and liver conditions Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs - a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations An economic model of long-term use of celecoxib in patients with osteoarthritis Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk Faecal blood loss with aspirin, nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors: systematic review of randomized trials using autologous chromium-labelled erythrocytes.Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials.Robustness of prevalence estimates derived from misclassified data from administrative databases.Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study Topical NSAID therapy for musculoskeletal pain.Do coxibs reduce prescription of gastroprotective agents? Results of a record linkage study.Is pathology necessary to predict mortality among men with prostate-cancer?Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits.Changes in rates of upper gastrointestinal hemorrhage after the introduction of cyclooxygenase-2 inhibitors in British Columbia and Ontario.British Journal of Clinical Pharmacology review series. Clinical research methods in gastroenterology.Efficacy of celecoxib, meloxicam and paracetamol in elderly Kashin-Beck disease (KBD) patients Adverse Drug Events Involving COX-2 Inhibitors.Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs.Age and rising rates of cyclooxygenase-2 inhibitor use. Results from a national survey Have COX-2 inhibitors influenced the co-prescription of anti-ulcer drugs with NSAIDs?A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin.Cyclooxygenase-2 inhibitors: do they have a role in emergency department prescribing?Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract.Treatment of chronic pain in persons with dementia: an overview.Reader's guide to critical appraisal of cohort studies: 1. Role and design Are rates of gastrointestinal bleeding higher following the introduction of COX-2 inhibitors?Celecoxib and cardiovascular risks.COX-2 inhibitors and the heart: are all coxibs the same?

P2860

Q24240811-0DB126B7-6E75-4E58-9A9B-5FAFE05961BE Q24244871-693960C7-2445-486B-853A-03369BE58CAC Q24529085-D71730DE-73F4-42F7-BA6D-E8A30A61A92A Q24657795-CA28A065-D715-4623-A2AD-26D8984C6403 Q24673561-4B6747BB-4C7E-4AD1-A16D-B446FBC1BE49 Q24804373-2AD1DD7B-755D-48F7-920D-3E57BC37737D Q24816687-9DFB9F6A-8095-4556-A0BB-1D21A48BE6EB Q26799236-087715E7-F176-4CD7-A0BE-8C25B67711F6 Q28069820-72802333-60DA-431C-A958-E91372B4B07A Q28186823-ED31B812-903F-4DE7-BDB3-97276B764694 Q28200569-42675C9A-B410-4C10-9670-7942159FF55B Q28200864-B2B2A8C3-750E-4409-A9CC-79423FFD7F50 Q28217824-750357E7-8C89-4B71-A710-37856F62473C Q28218005-9584EAE0-651D-403D-8559-311718F1FF32 Q28219220-34DA6F84-FA40-431C-86EE-ADA65E7EA523 Q30481876-AB5216BC-A79D-4998-86AE-4DBAC90CDE73 Q30540294-6165BA66-E1D6-49B0-8122-B8076204C4EB Q31109954-59C7BBA6-6B6F-4FC7-AE64-3A2DD1D2C416 Q33205361-2F9E0CC8-0295-42E4-85D3-AAC0C3B5E37E Q34310573-DB17E126-D318-40A3-B128-2EFDBD913AA7 Q34444119-AC80363A-CAEB-4D45-BFFC-4FB253040B52 Q34617511-D9318F86-DE26-4115-848A-884BBE08D925 Q34666402-ADFCCF67-925D-41D4-8BBD-67D267CBDD5E Q34769040-0511C404-4B29-413E-9FB5-85654853411A Q35108309-0A75FC38-5818-41B1-A2BC-B2394E7BA753 Q35165765-3692B278-7EEC-43F2-9722-532FC13D9B6C Q35190646-A97B7884-430C-4FB0-9989-023D8DA5A935 Q35197713-2840D0AA-23A4-4F5E-9F64-9398A708B6A4 Q35201026-38543AD1-25E7-4428-A67E-0A94F49B1291 Q35595971-8ED02928-C005-4F81-8C99-73D4570BB207 Q35688266-4270E91B-41D7-40ED-BB01-783AA30B1256 Q35825968-2CE862DD-2AB7-48B7-B43E-9F16EE634AC6 Q35827293-F339FCF4-2CAC-4219-A728-E4B384480227 Q35828904-72557E90-4D40-4DA6-B70A-E9120FF38BD1 Q35845845-6AF0931E-2128-4009-9608-0D4E870EF949 Q36063652-BDF982AE-8273-4585-A9EF-17B01B96DB08 Q36098734-64FBCB67-945D-47CC-801E-1498E7529173 Q36150589-DE288703-163D-4F05-9EA0-2C7460169066 Q36299969-E7FE576A-713E-4380-8C30-8DAD86F4B54B Q36441763-B56D5122-1AB1-4A3A-9F4F-AEAA520D13D8

P2860

Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs

http://www.wikidata.org/entity/Q34093824

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Observational study of upper g ...... roidal anti-inflammatory drugs

@ast

Observational study of upper g ...... roidal anti-inflammatory drugs

@en

Observational study of upper g ...... roidal anti-inflammatory drugs

@nl

type

label

Observational study of upper g ...... roidal anti-inflammatory drugs

@ast

Observational study of upper g ...... roidal anti-inflammatory drugs

@en

Observational study of upper g ...... roidal anti-inflammatory drugs

@nl

prefLabel

Observational study of upper g ...... roidal anti-inflammatory drugs

@ast

Observational study of upper g ...... roidal anti-inflammatory drugs

@en

Observational study of upper g ...... roidal anti-inflammatory drugs

@nl

P1433

Q34093824-4D4D4C46-2F5E-4A1B-BE4B-1EB91F003411

P1476

Q34093824-032E08A7-A0F9-4A2B-BFD3-8C7846991517

P2093

Q34093824-3F951045-3E84-45B3-908B-58DC73556CE1

Q34093824-52DC52D1-5DDF-47F5-BD9B-F4A036B7412A

Q34093824-5B68B4A0-1CC9-418A-A206-606D14311125

Q34093824-5B9F1C87-E0A7-4126-830E-75830AA345F0

Q34093824-6B3EC434-3CE6-4823-B426-2F6DEC2C9726

Q34093824-70EA705E-0874-4FA4-BA3D-58C8587B60D1

Q34093824-A11C8F5F-3955-471E-80A2-C9D2097D4DB1

Q34093824-F2A8AFE7-0AAA-4BBF-BC40-8CB020A2594A

P2860

Q34093824-005EFB9A-C152-4112-A597-2B8D27337C86

Q34093824-14B7B3EA-A3FA-48C4-928E-FE9978D1047B

Q34093824-28FE7350-F1F0-409D-B49D-A3D9279F5F9B

Q34093824-2DA42284-612F-45FA-9BE7-41B0F2718F18

Q34093824-338F0CCC-1AD9-4643-8BD5-9624C8C36F38

Q34093824-5BA4F41F-F792-4CAC-B94E-D8D2C392BE88

Q34093824-676A1F5B-5131-44C8-95C9-CE95C78AE2A7

Q34093824-843DD5D4-C611-4183-8B4C-B25B50F1E421

Q34093824-84E3E437-E4D3-4897-88BE-77FDF806D06F

Q34093824-85E508DB-A1D0-4295-94F5-A79B128A9910

P304

Q34093824-49B1877E-0410-4D1C-8D70-EE80B420A76F

P31

Q34093824-B8B39300-32DB-4273-ACE3-51751EB3D2ED

P356

Q34093824-C4AC8486-6AD8-4F89-A986-83C12642D7C7

P407

Q34093824-F55A4ED5-C596-487E-BDB9-51A96EC7D8FB

P433

Q34093824-5397B73C-6938-4B35-861E-92A0439FAE46

P478

Q34093824-DDDF9FFD-98DD-4873-987D-3855DBD6A0EF

P577

Q34093824-798BB154-6727-4D05-9AE0-D62DB07BD4BC

P5875

Q34093824-37CF7327-EB4A-4297-86DF-D09D1A29F2C7

P698

Q34093824-AF7C271D-44EE-40C8-AA0E-3AE77254223C

P921

Q34093824-4C8D1978-9A6D-454A-829A-28C55BA951FE

Q34093824-F1A3D22C-3109-4060-9942-F98061868617

P932

Q34093824-AA248E19-D645-4D1F-824B-9900A77C70CB

P356

BMJ.325.7365.624

P1433

P1476

Observational study of upper g ...... roidal anti-inflammatory drugs

@en

P2093

Alex Kopp

http://www.w3.org/2001/XMLSchema#string

Andreas Laupacis

http://www.w3.org/2001/XMLSchema#string

David N Juurlink

http://www.w3.org/2001/XMLSchema#string

Gary Naglie

http://www.w3.org/2001/XMLSchema#string

Geoffrey M Anderson

http://www.w3.org/2001/XMLSchema#string

Muhammad Mamdani

http://www.w3.org/2001/XMLSchema#string

Paula A Rochon

http://www.w3.org/2001/XMLSchema#string

Peter C Austin

http://www.w3.org/2001/XMLSchema#string

P2860

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Epidemiology of NSAID-related gastroduodenal mucosal injury

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.

Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?

Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s.

The coxibs, selective inhibitors of cyclooxygenase-2.

P304

624

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.325.7365.624

http://www.w3.org/2001/XMLSchema#string

P407

P433

7365

http://www.w3.org/2001/XMLSchema#string

P478

325

http://www.w3.org/2001/XMLSchema#string

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11149064

http://www.w3.org/2001/XMLSchema#string

P698

12242172

http://www.w3.org/2001/XMLSchema#string

P921

P932

126302

http://www.w3.org/2001/XMLSchema#string